Aralez Pharma (ARLZ): Catalysts Ahead - Guggenheim
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Guggenheim analyst, Louise Chen, reiterated her Buy rating on shares of Aralez Pharmaceuticals (NASDAQ: ARLZ) and commented on upcoming catalysts for the company. The analyst expects approval of Yosprala on its PDUFA date on 9/14. ARLZ has been preparing for the launch by expanding its cardiovascular salesforce and launching promotional efforts for its other cardiovascular drugs. If approved, the company should launch the drug in 4Q16. She estimates peak sales of $200MM by '22, which is not fully reflected in consensus expectations.
Shares of Aralez Pharmaceuticals closed at $4.69 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Guggenheim Reiterates Buy on United Natural Foods (UNFI) Following 1Q Report
- Jefferies Downgrades SL Green Realty (SLG) to Hold
- Lionsgate (LGF): Starz Deal Accretive To A Cheap Stock - Brean Capital
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View
Related EntitiesLouise Chen, PDUFA, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!